• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Hum Genet . ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population

tetano

Editor, Senior Moderator
Eur J Hum Genet


. 2020 Jul 17.
doi: 10.1038/s41431-020-0691-z. Online ahead of print.
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population


Elisa Benetti[SUP] 1 [/SUP], Rossella Tita[SUP] 2 [/SUP], Ottavia Spiga[SUP] 3 [/SUP], Andrea Ciolfi[SUP] 4 [/SUP], Giovanni Birolo[SUP] 5 [/SUP], Alessandro Bruselles[SUP] 6 [/SUP], Gabriella Doddato[SUP] 7 [/SUP], Annarita Giliberti[SUP] 7 [/SUP], Caterina Marconi[SUP] 8 [/SUP], Francesco Musacchia[SUP] 9 [/SUP], Tommaso Pippucci[SUP] 10 [/SUP], Annalaura Torella[SUP] 11 [/SUP], Alfonso Trezza[SUP] 3 [/SUP], Floriana Valentino[SUP] 7 [/SUP], Margherita Baldassarri[SUP] 7 [/SUP], Alfredo Brusco[SUP] 5 12 [/SUP], Rosanna Asselta[SUP] 13 14 [/SUP], Mirella Bruttini[SUP] 2 7 [/SUP], Simone Furini[SUP] 1 [/SUP], Marco Seri[SUP] 8 10 [/SUP], Vincenzo Nigro[SUP] 9 11 [/SUP], Giuseppe Matullo[SUP] 5 12 [/SUP], Marco Tartaglia[SUP] 4 [/SUP], Francesca Mari[SUP] 2 7 [/SUP], GEN-COVID Multicenter Study; Alessandra Renieri[SUP] 15 16 [/SUP], Anna Maria Pinto[SUP] 2 [/SUP]



Collaborators, Affiliations

Abstract

In December 2019, an initial cluster of interstitial bilateral pneumonia emerged in Wuhan, China. A human-to-human transmission was assumed and a previously unrecognized entity, termed coronavirus disease-19 (COVID-19) due to a novel coronavirus (SARS-CoV-2) was described. The infection has rapidly spread out all over the world and Italy has been the first European country experiencing the endemic wave with unexpected clinical severity in comparison with Asian countries. It has been shown that SARS-CoV-2 utilizes angiotensin converting enzyme 2 (ACE2) as host receptor and host proteases for cell surface binding and internalization. Thus, a predisposing genetic background can give reason for interindividual disease susceptibility and/or severity. Taking advantage of the Network of Italian Genomes (NIG), here we mined whole-exome sequencing data of 6930 Italian control individuals from five different centers looking for ACE2 variants. A number of variants with a potential impact on protein stability were identified. Among these, three more common missense changes, p.(Asn720Asp), p.(Lys26Arg), and p.(Gly211Arg) were predicted to interfere with protein structure and stabilization. Rare variants likely interfering with the internalization process, namely p.(Leu351Val) and p.(Pro389His), predicted to interfere with SARS-CoV-2 spike protein binding, were also observed. Comparison of ACE2 WES data between a cohort of 131 patients and 258 controls allowed identifying a statistically significant (P value < 0.029) higher allelic variability in controls compared with patients. These findings suggest that a predisposing genetic background may contribute to the observed interindividual clinical variability associated with COVID-19, allowing an evidence-based risk assessment leading to personalized preventive measures and therapeutic options.
 
Back
Top